Sarcopenia is common but its measured prevalence varies sharply with diagnostic criteria, age, setting and population. The evidence below separates pooled estimates from observed ranges and keeps related osteosarcopenia findings distinct.
Key Sarcopenia Statistics
The most broadly useful figures include:
- In the global review, pooled sarcopenia prevalence was 10%–27% among 692,056 adults, across studies included through the review search.
- Across global studies, reported sarcopenia prevalence ranged from 0.2% to 86.5%, reflecting differing definitions and populations.
- Among adults aged 60 and older, reported sarcopenia prevalence was 10%–27%, in the global meta-analysis evidence base.
- Severe sarcopenia prevalence was 2%–9%, in global adult studies included through the review search.
- In community-dwelling adults older than 60, prevalence was 11% in men and 9% in women, in the community setting meta-analysis.
- In nursing-home residents older than 60, prevalence was 51% in men and 31% in women, in the setting comparison review.
- Among hospitalized adults older than 60, prevalence was 23% in men and 24% in women, in the setting comparison review.
- In the nursing-home meta-analysis, EWGSOP-defined prevalence was 41%, among residents aged 60 and older.
- Worldwide osteosarcopenia prevalence was 18.5%, across 63 studies available through February 2023.
- Osteosarcopenia prevalence was 24.8% among people aged 80 and older, in the worldwide review through February 2023.
- Sarcopenia was associated with a 1.93 hazard ratio for falls, versus robust older adults in prospective studies identified through 2022.
- Sarcopenia was associated with a 2.25 hazard ratio for fractures, versus robust older adults in prospective studies identified through 2022.
- Sarcopenia was associated with a 1.52 hazard ratio for hospital admission, versus robust older adults in prospective studies identified through 2022.
- Across 56 meta-analyzed studies, sarcopenia was associated with a 2.00 hazard ratio for mortality, in literature through April 6, 2020.
- Sarcopenia was associated with a -0.76 standardized mean difference in health-related quality of life, across 43 observational studies through October 2022.
- The individual-patient-data SarQoL analysis found a -12.32-point mean difference, comparing sarcopenic and non-sarcopenic individuals in studies through March 2023.
Contents
- Global prevalence and diagnostic differences
- Prevalence by care setting
- Age, sex and osteosarcopenia data
- Falls, fractures, hospitalization and disability
- Mortality statistics
- Quality-of-life outcomes and study-period patterns
Global Sarcopenia Prevalence Statistics and Diagnostic Differences
The global systematic review identified 263 eligible studies for narrative synthesis and 151 for quantitative meta-analysis. The quantitative evidence included 692,056 adults with a mean age of 68.5 years, and the period was the set of studies included through the review search.
- The pooled prevalence range was 10%–27%, but classifications, instruments and cutoffs differed.
- The narrative review reported an observed range of 0.2%–86.5% across included studies.
- Among adults younger than 60, reported prevalence was 8%–36%; few studies covered this group and diagnostic criteria varied.
- Among adults aged 60 and older, the meta-analysis range was 10%–27%.
- Severe sarcopenia prevalence was 2%–9%, with fewer studies and varying severity definitions.
These figures should not be collapsed into one universal rate. The source describes a random-effects meta-analysis and emphasizes that definition and cutoff differences make estimates non-interchangeable: Global prevalence of sarcopenia and severe sarcopenia.
Sex comparisons also changed with the diagnostic framework. Using EWGSOP2, prevalence was 11% in men versus 2% in women, while using IWGS it was 17% in women versus 12% in men; these estimates are not directly comparable because the frameworks differ.
Sarcopenia Prevalence by Community, Hospital and Nursing-Home Setting
Care setting is one of the clearest differences in sarcopenia data. The setting comparison review covered adults older than 60 and used varied validated diagnostic criteria.
| Setting and population | Men | Women |
|---|---|---|
| Community-dwelling adults | 11% (95% CI 8%–13%) | 9% (95% CI 7%–11%) |
| Hospitalized adults | 23% | 24% |
| Nursing-home residents | 51% (95% CI 37%–66%) | 31% (95% CI 22%–42%) |
Source: Differences in the Prevalence of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. Hospital populations are not representative of community-dwelling older adults, and nursing-home tools and settings varied substantially.
A separate nursing-home meta-analysis included 16 studies, 3,585 participants and 129 nursing homes. Its criteria-specific results were 41% using EWGSOP across 12 studies and 2,685 cases, compared with 59% using skeletal-muscle-index criteria across three studies and 643 cases; those estimates should not be treated as equivalent.
The same nursing-home review found EWGSOP-defined prevalence of 46% in women and 43% in men, based on eight studies for each sex. Diagnosed malnutrition was associated with 1.74-fold higher odds of EWGSOP-defined sarcopenia, pooled from three studies and 718 cases, while malnutrition risk was not clearly associated, with OR 1.01 from two studies and 379 cases.
Source: Prevalence and Associated Factors of Sarcopenia in Nursing Home Residents. These are observational associations, and the confidence interval for malnutrition risk crossed the null.
Age, Sex and Osteosarcopenia Statistics
Osteosarcopenia combines bone and muscle conditions; it is related to, but not synonymous with, sarcopenia. The worldwide review included studies through February 2023 and found very high heterogeneity, with I² of 98.7%.
| Osteosarcopenia subgroup | Pooled prevalence |
|---|---|
| Overall, 63 studies | 18.5% (95% CI 16.7%–20.3%) |
| Younger than 80 | 17.8% |
| Age 80 and older | 24.8% (95% CI 17.0%–32.7%) |
| Men | 15.3% (95% CI 13.2%–17.4%) |
| Women | 19.4% (95% CI 16.9%–21.9%) |
| Hospital settings | 24.7% (95% CI 21.0%–28.3%) |
| Community settings | 12.9% (95% CI 10.7%–15.0%) |
Across individual studies, osteosarcopenia prevalence ranged from 1.50% to 64.30%. Regional subgroup estimates were 22.9% in Oceania, 21.6% in Africa, 20.8% in South America and 10.7% in Europe; regional evidence was uneven and European samples were relatively small.
Source: Global epidemiological features and impact of osteosarcopenia. The review’s combined-condition estimates should not be relabeled as sarcopenia-alone prevalence.
Sarcopenia Statistics for Falls, Fractures, Hospitalization and Disability
Prospective studies identified through 2022 associated sarcopenia with several adverse outcomes versus robust older adults. The estimates are pooled observational associations, not proof that sarcopenia caused each outcome.
- Falls: HR 1.93 (95% CI 1.29–2.87), across 35 prospective studies.
- Fractures: HR 2.25 (95% CI 1.77–2.86).
- Hospital admission: HR 1.52 (95% CI 1.28–1.80).
- Disability: HR 2.74 (95% CI 1.73–4.34), with disability definitions varying.
Source: The Relationship between Sarcopenia and Injury Events.
A separate hospitalization review identified through 2018 found pooled HR 1.57 (95% CI 1.26–1.94) across five studies and 2,832 participants. The subgroup HR was 2.01 (95% CI 1.41–2.88) among already hospitalized older patients and 1.40 (95% CI 1.05–1.88) among community-dwelling older people; studies with at least three years of follow-up produced HR 1.52, while shorter follow-up produced HR 1.76 that was not statistically significant (95% CI 0.90–3.44).
Source: Sarcopenia as a predictor of hospitalization among older people.
For osteosarcopenia, cohort studies through February 2023 found HR 1.54 for falls across three cohorts and HR 2.13 for fracture across seven cohorts. Fracture HR was 2.36 in prospective cohorts and 1.61 in retrospective cohorts, showing why study design matters.
Sarcopenia Mortality Statistics Across Populations and Follow-Up
The mortality review covered literature through April 6, 2020. It included 57 studies in the systematic review and 56 in the meta-analysis, with 42,108 participants whose mean ages ranged from 49.4 to 86.6 years across community, outpatient, inpatient and nursing-home populations.
- Sarcopenia was associated with HR 2.00 for mortality (95% CI 1.71–2.34).
- The same evidence base produced OR 2.35 for mortality (95% CI 1.64–3.37).
- Women represented 40.3% of participants; this describes study composition, not a sex-specific mortality estimate.
HRs and ORs are different measures and should not be treated as identical. Source: Sarcopenia Is Associated with Mortality in Adults.
The injury-outcome meta-analysis identified through 2022 reported HR 2.09 for death versus robust older adults (95% CI 1.71–2.55). In the osteosarcopenia review through February 2023, osteosarcopenia was associated with HR 1.75 for mortality (95% CI 1.34–2.28) across five cohort studies.
Sarcopenia Quality-of-Life Data and Osteosarcopenia Study-Period Patterns
Across 43 observational studies through October 2022, sarcopenia was associated with HRQoL SMD -0.76 (95% CI -0.95 to -0.57), with moderate-rated evidence and I² of 93%. The SarQoL-specific subgroup was -1.09 (95% CI -1.44 to -0.74), while generic questionnaires produced -0.49 (95% CI -0.63 to -0.36).
A separate individual-patient-data SarQoL review searched through March 2023, identified 413 records and included 32 studies, including 10 studies with unpublished data. It found a mean difference of -12.32 SarQoL points (95% CI -15.27 to -9.37) between sarcopenic and non-sarcopenic individuals.
Source: Sarcopenia and health-related quality of life.
The osteosarcopenia review also grouped prevalence by study period, but these are not chronological population trends in incidence:
| Study period | Prevalence | Evidence base |
|---|---|---|
| 2012–2014 | 7.4% | 2 studies; 2,227 participants |
| 2015–2017 | 18.1% | 8 studies; 19,662 participants |
| 2018–2020 | 21.7% | 30 studies; 18,231 participants |
| 2021–2023 | 16.7% | 23 studies; 23,249 participants |
Retrospective cohorts reported osteosarcopenia prevalence of 30.0% (95% CI 20.4%–39.6%), compared with 10.7% (95% CI 7.6%–13.9%) in prospective cohorts. Study design can introduce selection and information bias, so these subgroup estimates are not directly interchangeable.
Source: Global epidemiological features and impact of osteosarcopenia.